Dr. Kim attended Kyungpook University School of Medicine in Korea, where he obtained his medical degree. While studying at Kyungpook University Dr. Kim received high honors graduating Summa cum laude. He then continued his education by attending University of Iowa to study radiobiology and biophysics. Dr. Kim graduated from the University of Iowa receiving his Ph.D. in both subjects.

After completing both degrees Dr. Kim served as an intern at Montefiore Hospital in the Bronx, New York. After his internship Dr. Kim did his residency training in the department of radiation oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. While a resident at Sloan-Kettering Cancer Center, Dr. Kim also served as a research associate at the Sloan-Kettering Institute for Cancer Research in the biophysics division.

During his career Dr. Kim has been received many academic and hospital appointments which include:

• Member and Professor at Memorial Sloan-Kettering Cancer Center
• Professor of Radiation Oncology at Case Western Reserve University in Cleveland, OH
• Professor at Wayne State University School of Medicine in Detroit MI
• Chairman of the Department of Radiation Oncology at Henry Ford Hospital, Detroit, MI. He is currently a Chairman emeritus at the same institution.

He has also served as a consultant in several capacities including:

• Editorial board member of Radiation Research, Clinical Cancer bulletin
• Member of the Radiation study section and Sub-committee D of National Cancer Institute of NIH
• Scientific reviewer of Department of Defense, Washington D.C.

Dr. Kim is also a member of several professional societies which include: Radiation Research Society, American Association of Cancer Research, American Medical Association, American Society of Clinical Oncology, Michigan Radiological Society and many more.

Clinical Areas of Interests and Expertise

• Clinical expertise: CNS tumors, Soft Tissue Sarcomas, Malignant Lymphomas, and Endocrine Tumors; Stereotactic Radiosurgery
• Areas of Clinical Research: Combined Use of Targeted drugs and Radiation Therapy; Combined Use of Gene Therapy and Radiation Therapy; Radiation Protection and Mitigation of Normal Tissue Radiobiology.

Honors and Awards:

• Fellow, American College of Radiology (FACR), 1986
• Doctorate in Medical Science (Honorary Degree), Kyungpook University, Korea, 1990
• Herndon Chair in Oncology Research, Henry Ford Health System, 1990
• Distinguished Alumni Lecturer, Kyungpook University, Taegu, Korea, 1996
• Florence Chu Lecturer, Memorial Sloan-Kettering Cancer Center, New York, NY, 1997
• 'Top Doctors' in Consumer's Guide - 2002
• 'Best Doctors in America' - 2003-2007
• 'Top Doctors in Cancer' - 2005-2007

Publications (selected peer-reviewed from 220 publications):

1. Kim J, Li S, Pradhan D, Hammoud R, Chen Q, Yin FF, Zhao Y, Kim JH, Movsas B.(2007 ). 'Comparison of similarity measures for rigid-body CT/Dual X-ray image registrations.'Technol Cancer Res Treat. Aug;6(4): 337-46.
2. Barton KN, Freytag SO, Nurushev T, Yoo S, Lu M, Yin FF, Li S, Movsas B, Kim JH, Brown SL. (2007). 'A model for optimizing adenoviral delivery in human cancer gene therapy trials.' Hum Gene Ther. Jun;18(6): 562-72.
3. Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D, Nall C, Lu M, Ajlouni M, Movsas B, Kim JH. (2007) 'Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.' Mol Ther. Sep;15(9):1600-6. Epub Jun 12.
4. Freytag SO, Stricker H, Movsas B, Kim JH. (2007). 'Prostate cancer gene therapy clinical trials.' Mol Ther. Jun;15(6):1042-52. Epub Apr 3.
5. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. (2007). 'Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer.' Mol Ther. May;15(5): 1016-23. Epub Mar 20.
6. Ryu S, Jin JY, Jin R, Rock J, Ajlouni M, Movsas B, Rosenblum M, Kim JH. (2007). 'Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery.' Cancer. Feb 1;109(3): 628-36.
7. Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M, Kim JH. (2007). 'Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer.' Mol Ther. Mar;15(3):636-42. Epub Jan 16.
8. Barton, K, Freytag, S. O., Kim, JH. Combined modality approach using gene therapy and radiation. Hermonat, P.L., ed, Transworld Research Network, Kerala India, 2007.
9. Siddiqui F, Barton KN, Stricker HJ, Steyn PF, Larue SM, Karvelis KC, Sparks RB, Kim JH, Brown SL, Freytag SO (2007). 'Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials.' Hum Gene Ther. 18(4): 312-22.
10. Kohl RR, Kolozsvary A, Brown SL, Zhu G, Kim JH. (2007). 'Differential radiation effect in tumor and normal tissue after treatment with ramipril, an angiotensin-converting enzyme inhibitor.' Radiat Res. 168(4): 440-5.
11. Brown SL, Freytag SO, Barton KN, Flynn MJ, Peck DJ, Dragovic AF, Jin R, Yeni YN, Fyhrie DP, Les CM, Zhu G, Kolozsvary A, Pitchford WC, Nathanson SD, Fenstermacher JD, Kim JH (2007). 'Reporter gene imaging using radiographic contrast from nonradioactive iodide sequestered by the sodium-iodide symporter.' Contrast Media Mol Imaging 2(5): 240-7.
12. Ryu S, Kolozsvary A, Jenrow KA, Brown SL, Kim JH (2007). 'Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time.' J Neurooncol. 82(2): 119-24.
13. Patel SH, Ajlouni M, Chapman R, Lu M, Movsas B, Kim JH. (2007). 'A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).' J Thorac Oncol. 2(9): 831-7.
14. Barton, K., Paielli, D., Zhang, Y., Koul, S., Brown, S., Lu, M., Seely, J., Kim, J.H., Freytag, S.O. 'Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and the ADP gene demonstrate greater efficacy without increased toxicity. Mol. Ther., 13: 347-356, 2006.